{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.9","upperLimit":"16.7","value":"10.1"},{"groupId":"OG001","lowerLimit":"-0.9","upperLimit":"41.4","value":"10.9"},{"groupId":"OG002","lowerLimit":"1.5","upperLimit":"37.4","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"46.5","value":"46.5"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"5.7","value":"5.7"},{"groupId":"OG002","lowerLimit":"13.2","upperLimit":"126.7","value":"70.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Week 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Tumor size was the sum of the longest diameters (or short axis measurements for lymph nodes) of the target lesions (TLs). Percentage change in tumor size was determined for participants with measurable disease at baseline. Baseline for Response evaluation criteria in solid tumors (RECIST) version 1.1 was defined as the last evaluable assessment prior to first IP dose. This outcome measure was assessed only for substudy 1 Part A.","dispersionType":"Full Range","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEDIAN","populationDescription":"Response evaluable set included all dosed participants who had measurable disease at baseline. Here, \"n\" (number analyzed in each raw) signifies the participants with available data that were analyzed for each timepoint for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-treatment) up to Week 6 and Week 15","title":"Percentage Change From Baseline in Tumor Size","type":"SECONDARY","unitOfMeasure":"Percentage change in tumor size"}